Erythropoietin for the Treatment of Subarachnoid Hemorrhage: A Feasible Ingredient for a successful Medical Recipe

Grasso, Giovanni; Tomasello, Giovanni; Noto, Marcello; Alafaci, Concetta; Cappello, Francesco

doi:10.2119/molmed.2015.00177

Cited by 15 publications

(6 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Erythropoietin is a hormone produced primarily by the kidneys and plays an essential role in the production of red blood cells. In animal studies, erythropoietin has been shown to have some neuroprotective properties through an indeterminate mechanism that seems to be unrelated to its function in erythropoiesis . It has been reported to reduce the severity of vasospasm.…”

Section: Resultsmentioning

confidence: 99%

“…In animal studies, erythropoietin has been shown to have some neuroprotective properties through an indeterminate mechanism that seems to be unrelated to its function in erythropoiesis. [105][106][107][108] It has been reported to reduce the severity of vasospasm. A phase II randomized trial that included 80 patients who received 30 000 U of intravenous erythropoietin or placebo every 48 hours for a total of 90 000 U showed a decreased incidence of severe vasospasm from 27.5% to 7.5% (P = .037), reduced DCI from 40% to 7.5% (P = .001), and better outcome at discharge (P = .039).…”

Section: Erythropoietinmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and experimental aspects of aneurysmal subarachnoid hemorrhage

et al. 2019

View full text Add to dashboard Cite

Aneurysmal subarachnoid hemorrhage (aSAH) continues to be associated with significant morbidity and mortality despite advances in care and aneurysm treatment strategies. Cerebral vasospasm continues to be a major source of clinical worsening in patients. We intended to review the clinical and experimental aspects of aSAH and identify strategies that are being evaluated for the treatment of vasospasm. A literature review on aSAH and cerebral vasospasm was performed. Available treatments for aSAH continue to expand as research continues to identify new therapeutic targets. Oral nimodipine is the primary medication used in practice given its neuroprotective properties. Transluminal balloon angioplasty is widely utilized in patients with symptomatic vasospasm and ischemia. Prophylactic “triple‐H” therapy, clazosentan, and intraarterial papaverine have fallen out of practice. Trials have not shown strong evidence supporting magnesium or statins. Other calcium channel blockers, milrinone, tirilazad, fasudil, cilostazol, albumin, eicosapentaenoic acid, erythropoietin, corticosteroids, minocycline, deferoxamine, intrathecal thrombolytics, need to be further investigated. Many of the current experimental drugs may have significant roles in the treatment algorithm, and further clinical trials are needed. There is growing evidence supporting that early brain injury in aSAH may lead to significant morbidity and mortality, and this needs to be explored further.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Erythropoietinmentioning

confidence: 99%

Clinical and experimental aspects of aneurysmal subarachnoid hemorrhage

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Trials targeting inflammation have had varied success. Erythropoietin-β, despite having mechanisms of action against vasospasm and inflammation ( 101 ), had no effect on cerebral vasospasm, but did reduce DCI and improve functional outcome ( 102 ). This was a small study and is at high risk for bias ( 103 ), so additional trials are needed.…”

Section: Thromboinflammation As a Therapeutic Target To Prevent DCImentioning

confidence: 99%

The Role of Thromboinflammation in Delayed Cerebral Ischemia after Subarachnoid Hemorrhage

et al. 2017

View full text Add to dashboard Cite

Delayed cerebral ischemia (DCI) is a major determinant of patient outcome following aneurysmal subarachnoid hemorrhage. Although the exact mechanisms leading to DCI are not fully known, inflammation, cerebral vasospasm, and microthrombi may all function together to mediate the onset of DCI. Indeed, inflammation is tightly linked with activation of coagulation and microthrombi formation. Thromboinflammation is the intersection at which inflammation and thrombosis regulate one another in a feedforward manner, potentiating the formation of thrombi and pro-inflammatory signaling. In this review, we will explore the role(s) of inflammation and microthrombi in subarachnoid hemorrhage (SAH) pathophysiology and DCI, and discuss the potential of targeting thromboinflammation to prevent DCI after SAH.

show abstract

“…В этом аспекте важно отметить, что действие антиоксидантов может осуществляться посредством различных механизмов, среди которых важным является локальное снижение концентрации кислорода и предотвращение его включения в окисление [3]. ЭПО, наряду с регуляцией эритропоэза, обладает и плейотропными свойствами: уменьшает окислительные повреждения при ишемии/реперфузии, снижает концентрацию фактора некроза опухоли-a, интерлейкина-6, а также улучшает процессы оксигенации в лёгких [22]. Данное вещество может непосредственно взаимодействовать со свободными радикалами и нейтрализовать их действие, выступая в качестве "ловушки" [23].…”

Section: результаты и обсуждениеunclassified

Participation of melatonin in regulation of blood oxygen-transport function in oxidative stress induced by injection of lipopolisaccharide

Зинчук

Firago

2017

BIOMED KHIM

View full text Add to dashboard Cite

The contribution of melatonin to the regulatoin of the blood oxygen transport function was studied during oxidative stress induced by a triple injection of lipopolysaccharide (at a dose of 5 mg/kg) in conditions of erythropoietin and gasetransmitters (nitrogen monoxide, hydrogen sulfide) action. In the experimental groups, intraperitoneal injections of melatonin (5 mg/kg), erythropoietin (1000 U/kg), hydrogen sulfide donor (NaHS 5 mg/kg), and L-arginine (100 mg/kg), were performed. The use of melatonin alone or in combination with erythropoietin, sodium hydrosulfide or L-arginine led to a decrease in lipid peroxidation products and an increase in the antioxidant protection. Melatonin, during lipopolysaccharide administration, caused changes of blood oxygen transport function: blood oxygen saturation increased, hemoglobin oxygen affinity increased. The modifying effect of melatonin on the blood oxygen transport function in combination with erythropoietin and gastransmitters did not exceed the effect of melatonin alone.

show abstract

Erythropoietin for the Treatment of Subarachnoid Hemorrhage: A Feasible Ingredient for a successful Medical Recipe

Cited by 15 publications

References 99 publications

Clinical and experimental aspects of aneurysmal subarachnoid hemorrhage

Clinical and experimental aspects of aneurysmal subarachnoid hemorrhage

The Role of Thromboinflammation in Delayed Cerebral Ischemia after Subarachnoid Hemorrhage

Participation of melatonin in regulation of blood oxygen-transport function in oxidative stress induced by injection of lipopolisaccharide

Contact Info

Product

Resources

About